Diaceutics (LON:DXRX) Sets New 12-Month High – What’s Next?

Diaceutics PLC (LON:DXRX) shares hit a new 52-week high on Tuesday. The stock traded as high as GBX 199.50 and last traded at GBX 199.50, with a volume of 550495 shares trading hands. The stock had previously closed at GBX 193.

Analyst Ratings Changes

Separately, Canaccord Genuity Group reiterated a “buy” rating and issued a GBX 215 price target on shares of Diaceutics in a research note on Tuesday, September 22nd. Two investment analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of GBX 215.

Diaceutics Stock Up 3.4%

The firm has a market cap of £169.30 million, a price-to-earnings ratio of -623.44 and a beta of 0.88. The company has a debt-to-equity ratio of 5.40, a current ratio of 2.55 and a quick ratio of 9.92. The stock has a 50-day moving average of GBX 156.70 and a 200-day moving average of GBX 153.82.

Diaceutics (LON:DXRX) last released its earnings results on Tuesday, September 22nd. The company reported GBX (3.27) earnings per share for the quarter. Diaceutics had a negative net margin of 0.66% and a negative return on equity of 0.68%. Sell-side analysts predict that Diaceutics PLC will post 1.0107919 EPS for the current fiscal year.

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world’s leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX – The Diagnostics Network®.